The blue and white Pfizer logo at the top of an office building against a clear, blue sky.
Image: © cbies/

Pfizer to create 300 new jobs across Irish sites

2 Nov 2020

A major multimillion-euro investment will support further development of Pfizer’s existing manufacturing sites in Ireland.

Today (2 November), pharma giant Pfizer announced an investment of approximately €300m in its Irish operations, which will create 300 new roles in Dublin, Kildare and Cork.

The investment will support further development of the company’s existing manufacturing sites in Grange Castle, Newbridge and Ringaskiddy, and will also include the initial construction stage of an additional development facility at the Ringaskiddy site.

Pfizer’s Irish sites manufacture vaccines and medicines in the areas of arthritis, inflammation, cancer, anti-infectives, haemophilia, pain and stroke.

The new facility in Ringaskiddy is expected to manufacture pharmaceutical compounds for Pfizer’s clinical trials globally, expanding the company’s role in Ireland into supporting earlier phases of new medicine development.

The 300 new roles will be filled over the next two to three years and will bring the company’s total headcount in Ireland to 4,000. The jobs include highly skilled roles such as analysts, technicians, engineers, scientists, technologists, quality specialists, data analysts and chemists.

Speaking at the announcement, Taoiseach Micheál Martin, TD, said the investment is a vote of confidence in the skills and talent of Irish people. “Over the past five decades, there has been a huge expansion of the sector in this country, creating thousands of jobs and solidifying Ireland’s reputation as a world leader in pharmaceutical innovation and manufacturing,” he said.

“Pfizer has made a significant contribution to the Irish economy and this latest investment is a testament to the quality and experience of the workforce here.”

Echoing the Taoiseach’s sentiments, IDA Ireland CEO Martin Shanahan said the investment “underscores Ireland’s reputation as a global location of excellence for biophramaceuticals”.

Dr Paul Duffy, vice-president of Pfizer Global Supply, added that it’s “particularly exciting” that the company’s Ringaskiddy site has been chosen to manufacture investigational compounds for its clinical trials globally. “We look forward to seeing that new facility become operational.”

For more information on all roles available at Pfizer Ireland, click here.

Jenny Darmody
By Jenny Darmody

Jenny Darmody became the editor of Silicon Republic in 2023, having worked as the deputy editor since February 2020. When she’s not writing about the science and tech industry, she’s writing short stories and attempting novels. She continuously buys more books than she can read in a lifetime and pretty stationery is her kryptonite. She also believes seagulls to be the root of all evil and her baking is the stuff of legends.

Loading now, one moment please! Loading